The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn s disease.
Target levels of infliximab in patients with IBD and high visceral adipose fat burden may be higher, suggesting the potential need to personalize dosing strategies.